vs
Side-by-side financial comparison of Primis Financial Corp. (FRST) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $45.6M, roughly 1.9× Primis Financial Corp.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 13.0%).
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FRST vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.6M | $86.8M |
| Net Profit | $7.3M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 16.0% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | 200.0% | — |
| EPS (diluted) | $0.30 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $86.8M | ||
| Q3 25 | $41.0M | $67.5M | ||
| Q2 25 | $43.2M | $60.0M | ||
| Q1 25 | $58.7M | $49.3M | ||
| Q4 24 | $38.8M | $73.7M | ||
| Q3 24 | $37.3M | $58.6M | ||
| Q2 24 | $35.7M | $31.1M |
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | — | ||
| Q3 25 | $6.8M | $-91.3M | ||
| Q2 25 | $2.4M | $-111.7M | ||
| Q1 25 | $22.6M | $-116.2M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $1.2M | $-83.5M | ||
| Q2 24 | $3.4M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | -84.7% | ||
| Q3 25 | 21.3% | -140.7% | ||
| Q2 25 | 6.9% | -189.8% | ||
| Q1 25 | 41.9% | -245.8% | ||
| Q4 24 | -123.0% | -117.5% | ||
| Q3 24 | -3.1% | -152.1% | ||
| Q2 24 | 7.8% | -327.6% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 16.7% | -135.3% | ||
| Q2 25 | 5.6% | -186.2% | ||
| Q1 25 | 38.6% | -235.5% | ||
| Q4 24 | -100.3% | — | ||
| Q3 24 | 3.3% | -142.7% | ||
| Q2 24 | 9.6% | -312.2% |
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | — | ||
| Q3 25 | $0.28 | — | ||
| Q2 25 | $0.10 | $-0.33 | ||
| Q1 25 | $0.92 | $-0.36 | ||
| Q4 24 | $-0.95 | $-0.24 | ||
| Q3 24 | $0.05 | $-0.28 | ||
| Q2 24 | $0.14 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.9M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $427.2M | $698.6M |
| Total Assets | $4.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $297.0M | ||
| Q3 25 | $63.9M | $300.8M | ||
| Q2 25 | $94.1M | $301.2M | ||
| Q1 25 | $57.0M | $359.7M | ||
| Q4 24 | $64.5M | $323.8M | ||
| Q3 24 | $77.3M | $397.5M | ||
| Q2 24 | $66.6M | $412.5M |
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $698.6M | ||
| Q3 25 | $382.2M | $702.3M | ||
| Q2 25 | $376.4M | $698.5M | ||
| Q1 25 | $375.6M | $767.9M | ||
| Q4 24 | $351.8M | $710.4M | ||
| Q3 24 | $381.0M | $773.5M | ||
| Q2 24 | $376.0M | $768.5M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $913.2M | ||
| Q3 25 | $4.0B | $904.9M | ||
| Q2 25 | $3.9B | $907.4M | ||
| Q1 25 | $3.7B | $966.7M | ||
| Q4 24 | $3.7B | $910.4M | ||
| Q3 24 | $4.0B | $991.1M | ||
| Q2 24 | $4.0B | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $-52.6M | ||
| Q3 25 | $-11.4M | $-78.7M | ||
| Q2 25 | $-41.0M | $-67.4M | ||
| Q1 25 | $34.4M | $-103.7M | ||
| Q4 24 | $19.5M | $-73.3M | ||
| Q3 24 | $6.1M | $-59.0M | ||
| Q2 24 | $52.3M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | $18.3M | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | 47.3% | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 3.1% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.0% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | — | ||
| Q2 25 | -16.82× | — | ||
| Q1 25 | 1.52× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.93× | — | ||
| Q2 24 | 15.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
